CRISPR/Cas9 Beta-globin Gene Targeting: A method to reach a therapeutic target in Sickle cell disease

  • سال انتشار: 1397
  • محل انتشار: سومین کنگره بین المللی پزشکی شخصی ایران
  • کد COI اختصاصی: IPMCMED03_035
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 550
دانلود فایل این مقاله

نویسندگان

Mina Ebrahimi

Research center of thalassemia & hemoglobinopathy, Health research institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Mohammad Ali Jalalifar

Research center of thalassemia & hemoglobinopathy, Health research institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

چکیده

Introduction: Sickle cell disease (SCD) is one of the most common monogenic disorders worldwide. SCD is caused by an A-to-T point mutation in the sixth codon of the b-globin gene. SCD is associated with substantial morbidity, poor quality of life, and a shortened life expectancy. An alternative to using allogeneic hematopoietic stem cells (HSCs) to cure the b-hemoglobinopathies is to use homologous recombination (HR) to directly modify the HBB gene in the patient’s own HSCs. It circumvents the need for a matched donor and thus avoids the risk of graft versus host disease and graft rejection after HSCT.Method: Two or three bone marrow harvests are required to collect an adequate dose of HSPCs from SCD patients. Recently suggested that plerixafor is potentially a safer mobilizing agent for SCD patients.Results: several months after gene therapy, the total Hb level was almost 12 g/dL, with therapeutic Hb and HbS accounting for 48% and 46% of the Hb tetramers, respectivelyConclusions: The CRISPR/Cas9 complex consists of the Cas9 endonuclease and a 100-nucleotide single guide RNA (sgRNA). Target identification relies first on the identification of a 3-base pair protospacer adjacent motif and then hybridization between a 20-nucleotide stretch of the sgRNA and the DNA target site, which triggers Cas9 to cleave both DNA strands. Genome editing by HR requires the delivery of a DNA donor molecule to serve as a homologous template, which the cellular homologous recombination machinery uses to repair the break by a ‘copy and paste’ method.

کلیدواژه ها

gene editing; sickle cell disease; Transfusion; CRISPER

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.